UCB Joins the Chase for Immune System Reset With $2B Acquisition
Candid Therapeutics brings to UCB two clinical-stage T cell engagers in development for autoimmune disorders. To accept UCB’s offer, Candid terminated its reverse merger with Rallybio.
Why Biogen Is Paying $5.6B to Buy Apellis Pharma
Biogen’s Apellis Pharmaceuticals acquisition comes nearly two years after the drugmaker purchased immunology startup Human Immunology Biosciences. CEO Chris Viehbacher said Apellis accelerates Biogen’s expansion in nephrology, supporting a HI-Bio drug currently in pivotal testing for three kidney conditions.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Taking a Page From Cancer Drugs, Autoimmune Biotech Alumis Aims for Precision Immunology
Alumis’s genomic research guided its development of envudeucitinib, a TYK2 inhibitor that some analysts now view as best in class. The Phase 3 results that will support a planned FDA submission in plaque psoriasis are scheduled for presentation this weekend during the American Academy of Dermatology annual meeting in Denver.
Gilead Sciences Gains an Opportunity for Immune System Reset With $1.7B Ouro Acquisition
Gilead Sciences is acquiring Ouro Medicines, a startup developing T cell engagers for a range of autoimmune diseases. Separately, Gilead is negotiating a deal with Galapagos to share in the development and potential commercialization of the Ouro drug.
Candid Therapeutics Strikes Up Merger With Rallybio to Advance Its Autoimmune Drug Pipeline
Along with the reverse merger, Candid Therapeutics announced $505 million in private financing to support its pipeline of T cell engagers for autoimmune disease. Lead program cizutamig is on track to begin global Phase 2 testing in myasthenia gravis and interstitial lung disease.
Boehringer Boosts Pipeline, Adding Oral Small Molecules With Broad Immunology & Inflammation Potential
Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential applications in multiple autoimmune disorders. Depending on the progress of Boehringer’s research, Sitryx could receive more than $500 million.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B
Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by AstraZeneca, AbbVie, Gilead Sciences, and Bristol Myers Squibb.
Clinical Trial Win Bolsters Blockbuster Prospects for Roivant Rare Disease Drug Licensed From Pfizer
Brepocitinib is on track for pivotal testing after meeting the goals of a proof-of-concept study in cutaneous sarcoidosis, a rare inflammatory skin disorder with no FDA-approved therapies. Roivant Sciences subsidiary Priovant Therapeutics licensed the dual JAK1 and TYK2 inhibitor from Pfizer.
WellTheory Introduces Autoimmune Postpartum Program
WellTheory launched a postpartum program to help women manage autoimmune symptoms triggered by hormonal changes after childbirth.
Startup Fortitude Bio Launches to Beat Drug Resistance in Cancer, Expand ADCs to Autoimmune Disease
Fortitude Biomedicines is developing antibody drug conjugates that use targeted protein degraders as their therapeutic payloads. The startup joins a group of degrader ADC (or DAC) developers that includes Bristol Myers Squibb and Pfizer.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
FDA Approval for Roche Cancer Drug Brings a New Biologic Option to Lupus Nephritis
Roche’s Gazyva, which first reached the market as a blood cancer drug, has expanded its FDA approval to include treatment of the autoimmune disorder lupus nephritis. The CD20-targeting antibody can now compete against a blockbuster GSK drug that is the standard biologic therapy for the debilitating kidney condition.
WellTheory Raises $14M to Expand Autoimmune Care Platform
WellTheory's Series A round was led by General Catalyst and included participation from 7wireVentures, Ingeborg Investments, Accel, Box Group, Leaps by Bayer and Up2 Opportunity Fund.
BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition
Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies.
Startup Nilo Launches With $101M for Autoimmune Drugs That Target ‘Brain-Body Circuits’
Nilo Therapeutics’ Series A round was led by The Column Group, DCVC Bio, and Lux Capital. The preclinical startup is developing drugs targeting neural circuits that control systemic inflammation.
Two Is Better Than One: Startup Dualitas Lands $65M to Bring Bispecific Drugs to Autoimmune Disease
Dualitas Therapeutics designs bispecific antibodies to hit to two targets on the same immune cell, leveraging proximity biology to provide benefit beyond what’s possible with monoclonal antibody drugs. Eli Lilly and Chugai Pharmaceutical are among the investors in the immunology and inflammation startup.